Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007097 (carcinoma)
 152,788 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A phase II study of 5-FU tablet for 52 patients with cancer of the uterine cervix was undertaken by a cooperative study group consisting of 13 institutions. The clinical response rate in 44 evaluable cases was 31.8% (CR: 3 cases, PR: 11 cases, MR: 2 cases, NC: 19 cases and PD: 9 cases). Efficacy rates of 5-FU tablet according to lesion sites were 44.4% in the uterine cervix, 42.9% in the vaginal wall and cut vaginal end, 25.0% in the lymph nodes and 16.7% in the lung. Histologically, the effectiveness rate was 26.9% for large-cell, non-keratinizing-type-carcinoma, 42.9% for small-cell, non-keratinizing-type, and 60.0% for the keratinizing-type of squamous cell carcinoma. One of three adenocarcinoma cases (33.3%) showed improvement. Some adverse effects were observed in 16 (32.0%) of 50 evaluable cases. A large proportion of the adverse effects were gastro-intestinal disorders, such as nausea, vomiting and anorexia. These results suggested that 5-FU tablet is a useful chemotherapeutic agent against carcinoma of the uterine cervix.
 ...
PMID:[Phase II study of 5-FU tablets in cancer of the uterine cervix]. 360 56

The effect of cis-diamminedichloro platinum (II) (CDDP) was evaluated in 14 patients with advanced pancreatic carcinoma. Prior chemotherapy was done in 7 cases and the remaining 7 were fresh cases. The drug was given at a dose of 80 mg/m2 I.V. every 3 weeks, with hydration and mannitol diuresis. Four cases out of 14 showed no change, while the remaining 10 cases showed progressive disease. The response rate was 0%. Most of the patients who showed myelosuppression had received prior chemotherapy. Non-hematologic toxicity occurred in 9 patients (64%) and consisted of nausea in 9, vomiting in 7 and anorexia in 9. Values of serum creatinine and BUN were transiently elevated.
 ...
PMID:[Cis-diamminedichloroplatinum(II) chemotherapy in advanced pancreatic carcinoma]. 367 95

The case of a patient with malignant degeneration of a solitary abdominal schwannoma and endobronchial metastasis is presented. The patient presented clinically with dyspnea referable to her lung mass, anorexia, and night sweats. The lung mass, initially diagnosed as a large-cell undifferentiated carcinoma, was later found to be histologically identical to the malignant portion of the abdominal tumor. The light microscopic, electron microscopic, and immunoperoxidase staining characteristics of the tumor are reported, and previous reports in the literature are reviewed.
 ...
PMID:Malignant epithelioid peripheral nerve sheath tumor arising in a benign schwannoma. 368 24

Echinomycin was administered to patients with advanced carcinoma in escalating doses ranging from 60 to 1500 micrograms/m2 given weekly by 15-minute iv infusions for four doses, with a subsequent 2-week rest period. Dose-limiting nausea, vomiting, and anorexia associated with varying degrees of renal and hepatic dysfunction proved dose-limiting at the 1500-micrograms/m2 level. Thrombocytopenia was noted in 15% of patients receiving greater than or equal to 700 micrograms/m2 and was severe in 11% without an evident dose-response relationship. Leukopenia was rare and mild when encountered. Allergic reactions were observed. Phase II trials are feasible using a dose schedule of 1200 micrograms/m2/week X 4 weeks.
 ...
PMID:Phase I study of echinomycin. 369 May 32

A case of pancreatic carcinoma in a 14-year-old Japanese boy is reported. He complained of general fatigue, anorexia, abdominal distension, and abdominal mass. At autopsy, a whitish tumor was found from the head to the body of the pancreas. Metastasis was found in the liver, lungs, gall bladder, and various lymph nodes such as stomach, hilus, and periaorta. The tumor was histologically determined to be moderately differentiated adenocarcinoma (cribriform type) of duct cell origin. However, the tumors showed PAS-positive diastase-resistant mucus in the cytoplasm. Histocytology showed the positivity for alpha 1-antitrypsin, secretory component (sc), and CEA, but no S-amylase was detected in the cytoplasm. Electron microscopy revealed zymogen-like granules in the cytoplasm suggesting acinar differentiation.
 ...
PMID:Pancreatic carcinoma in childhood. 370 61

Malignant histiocytosis was diagnosed in 10 male and 1 female Bernese Mountain Dogs. Nine of these dogs were closely related. The disease was characterized by a rapidly progressive and inevitably fatal course. Clinical signs varied, but lethargy, anorexia, weight loss, and respiratory and CNS abnormalities predominated. The lungs were the primary site of tumor involvement in 10 dogs. The eleventh dog had lymphadenopathy and severe anemia. Metastatic lesions were detected in all dogs. Anaplastic pulmonary carcinoma was diagnosed originally in 6 of the 11 cases, but this diagnosis was changed to malignant histiocytosis after electron microscopic examination of tissues and immunohistochemical identification of histiocytic markers in the tumor cells.
 ...
PMID:Malignant histiocytosis in Bernese Mountain dogs. 371 Aug 88

Two closely related lines of the same Walker 256 carcinoma in Crl-CD/COBS rats, described as behaving differently as regards tumor growth and host reaction, show different chemotherapeutic sensitivity to cyclophosphamide (CPA). Line B, which induces early cachexia with marked anorexia, is only moderately sensitive to CPA, while line A, which causes mild anorexia and only terminal cachexia, shows marked responsiveness to CPA, cure being attained in 75% of animals treated with a single dose of 120 mg/kg and in 90-100% of those given 20 mg/kg every other day. Comparative studies in both tumor lines on the distribution of CPA in vivo and on its metabolism by the liver perfusion technique showed no appreciable differences between the two lines in the pharmacokinetics of the compound, but indicate a much greater metabolizing capacity of CPA in the Walker 256/A animals. In vitro metabolic and covalent binding studies confirm that the liver of the Walker 256/A group metabolizes and covalently binds twice as much CPA as the liver of the Walker 256/B group. Conversely to Walker B, microsomal preparations of the Walker tumor line A are able to metabolize CPA to intermediates which irreversibly bind to tissue macromolecules, suggesting an in situ activation of the compound in the sensitive Walker tumor.
 ...
PMID:Different sensitivity of two Walker 256 carcinoma lines to cyclophosphamide: correlation with drug distribution, biotransformation and macromolecule binding. 372 87

Adenocarcinoma of the esophagus is relatively rare. An 81-year-old man with the chief complaints of loss of appetite and general fatigue was admitted to our hospital. By X-ray and endoscopic examination, a diagnosis of esophageal carcinoma in the Ei and Ea areas was made. A biopsy specimen obtained by endoscopy showed moderately differentiated adenocarcinoma, and the tumor origin was recognized in the cardia of the stomach. Lower esophagofundectomy by left thoracolaparotomy was performed. The postoperative pathological diagnosis showed adenocarcinoma of the esophagus and the tumor expansively invading to the cardiac portion.
 ...
PMID:[Esophageal adenocarcinoma in an 81-year-old man]. 382 Jun 3

In the present study, the relationship between central catecholamine levels and the anorexia induced by Walker 256 carcinoma was investigated. Results indicate that the anorexia is not due to depletion of central catecholamines. Tumor bearing rats sacrificed at night, when spontaneous food intake is selectively depressed, showed increased norepinephrine levels in the hypothalamus, cortex and hippocampus and increased dopamine levels in the striatum, midbrain, and cortex. Increased nighttime hypothalamic norepinephrine levels were positively correlated with the magnitude of spontaneous food intake in tumor rats.
 ...
PMID:Brain catecholamine alterations accompanying development of anorexia in rats bearing the Walker 256 carcinoma. 385 31

Mitomycin was approved for marketing by the Food and Drug Administration in 1974 for use in gastric and pancreatic carcinomas when combined with other chemotherapeutic agents. Since then, mitomycin has been used extensively in combination chemotherapy for a variety of tumors, particularly in the past seven years. However, the contribution of this agent to the various drug regimens has not been adequately defined. Clear evidence of the drug's activity as a single agent has been seen in the intravesical treatment of superficial bladder carcinoma. Common toxicities include anorexia, vomiting, and myelosuppression. Less common, but potentially lethal, toxicities in the form of fibrosing alveolitis and microangiopathic hemolytic anemia with renal failure are being reported with increasing frequency. These potentially severe adverse effects, coupled with the still undefined role of mitomycin in systemic cancer chemotherapy, suggest that selection of this drug for other than investigational use should be made with care.
 ...
PMID:Mitomycin: ten years after approval for marketing. 388 63


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>